FENC
Price
$10.90Alerts
Change
+$0.26 (+2.44%)
Updated
Nov 12 closing price
Capitalization
344.01M
Earnings call today
Intraday BUY SELL Signals
SEPN
Price
$41.86Alerts
Change
-$6.70 (-13.80%)
Updated
Nov 12 closing price
Capitalization
2.28B
Intraday BUY SELL Signals
Interact to see
Advertisement

FENC vs SEPN

FENC vs SEPN Comparison Chart in %
View a ticker or compare two or three
VS
FENC vs. SEPN commentary
Nov 13, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FENC is a Hold and SEPN is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for FENC with price predictions
Nov 11, 2026

FENC in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 05, 2026

FENC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 39 cases where FENC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for FENC just turned positive on November 09, 2026. Looking at past instances where FENC's MACD turned positive, the stock continued to rise in 36 of 47 cases over the following month. The odds of a continued upward trend are 77%.

Following a +15.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where FENC advanced for three days, in 203 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FENC as a result. In 93 of 113 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

FENC moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FENC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for FENC entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.105) is normal, around the industry mean (3.498). FENC has a moderately low P/E Ratio (-81.750) as compared to the industry average of (-1.193). Projected Growth (PEG Ratio) (0.100) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.963) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. FENC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FENC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for SEPN with price predictions
Nov 11, 2026

Momentum Indicator for SEPN turns positive, indicating new upward trend

SEPN saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator turned positive. In 27 of the 28 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for SEPN just turned positive on October 20, 2026. Looking at past instances where SEPN's MACD turned positive, the stock continued to rise in 9 of 10 cases over the following month. The odds of a continued upward trend are 90%.

SEPN moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for SEPN crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 5 of 5 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Following a +7.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where SEPN advanced for three days, in 89 of 100 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.

The Aroon Indicator entered an Uptrend today. In 100 of 118 cases where SEPN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.

Bearish Trend Analysis

The 10-day RSI Indicator for SEPN moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 16 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 80%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 15 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SEPN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.

SEPN broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.896) is normal, around the industry mean (3.498). SEPN has a moderately low P/E Ratio (-92.170) as compared to the industry average of (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (17.361) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SEPN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SEPN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
FENC: Fundamental Ratings
FENC
OUTLOOK RATING
1..100
24
VALUATION
overvalued / fair valued / undervalued
1..100
3
Undervalued
PROFIT vs RISK RATING
1..100
87
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
48
P/E GROWTH RATING
1..100
44
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
FENCSEPN
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
74%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 4 days ago
74%
Bullish Trend 3 days ago
89%
Declines
ODDS (%)
Bearish Trend 8 days ago
82%
Bearish Trend 11 days ago
72%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
78%
Aroon
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
85%
COMPARISON
Comparison
Nov 13, 2026
Stock price -- (FENC: $10.64 vs. SEPN: $48.56)
Brand notoriety: FENC and SEPN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FENC: 171% vs. SEPN: 252%
Market capitalization -- FENC: $344.01M vs. SEPN: $2.28B
FENC [@Biotechnology] is valued at $344.01M. SEPN’s [@Biotechnology] market capitalization is $2.28B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FENC’s FA Score shows that 1 FA rating(s) are green while SEPN’s FA Score has 1 green FA rating(s).

  • FENC’s FA Score: 1 green, 4 red.
  • SEPN’s FA Score: 1 green, 4 red.
According to our system of comparison, FENC is a better buy in the long-term than SEPN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FENC’s TA Score shows that 3 TA indicator(s) are bullish while SEPN’s TA Score has 6 bullish TA indicator(s).

  • FENC’s TA Score: 3 bullish, 5 bearish.
  • SEPN’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, SEPN is a better buy in the short-term than FENC.

Price Growth

FENC (@Biotechnology) experienced а +2.80% price change this week, while SEPN (@Biotechnology) price change was +1.42% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.18%. For the same industry, the average monthly price growth was -2.37%, and the average quarterly price growth was -16.49%.

Reported Earning Dates

FENC is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (+7.18% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

SEPN and

Correlation & Price change

A.I.dvisor indicates that over the last year, SEPN has been loosely correlated with SRRK. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if SEPN jumps, then SRRK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SEPN
1D Price
Change %
SEPN100%
-7.22%
SRRK - SEPN
41%
Loosely correlated
-2.92%
TSHA - SEPN
41%
Loosely correlated
+0.12%
RYTM - SEPN
40%
Loosely correlated
-1.57%
PVLA - SEPN
39%
Loosely correlated
-2.83%
IMMX - SEPN
38%
Loosely correlated
+3.71%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SCLZ55.760.74
+1.35%
Swan Enhanced Dividend Income ETF (SCLZ)
JHML90.901.04
+1.15%
John Hancock Multifactor Large Cap ETF (JHML)
RFDA72.450.46
+0.64%
ALPS Dynamic US Dividend Advantage ETF (RFDA)
TAJX25.52N/A
N/A
Corgi India 2x Daily ETF (TAJX)
XTWO48.37-0.04
-0.08%
BondBloxx Bloomberg Two Year Target Duration US Treasury ETF (XTWO)